Diagnostic Biomarker Market
Global Diagnostic Biomarker Market Research By Application (Oncology, Cardiology, Neurology, Nephrology and Other), By Diagnostic Technique (Elisa, Colorimetric Assay, Liquid Chromatography-Mass Spectrometry, and Particle-Enhanced Turbidimetric Immunoassay and Other), and By End-User (Hospitals & Diagnostic Labs and Research Centers) Forecast Period (2021-2027) Forecast 2021-2027
The global diagnostic biomarker market is growing at a considerable CAGR of 12.9% during the forecast period. Rising number of research institute focusing on diagnostic biomarkers is one of the prime factors affecting and driving the market. Increasing advancement in biomedical technologies along with techniques related to laboratory is also estimated to be the prime factors that are contributing significantly towards the growth of the market. However, availability of resources that are limited along with high cost involvement are some major factors that are hindering the growth of the global diagnostic biomarker market across the globe.
Further, active funding availability for research institute is one of the key factors that are creating opportunity for the market. New product launches and collaboration in the market are likely to drive the growth of the global diagnostic biomarker market. For instance, in February 2020, Biodesix had set forth the commencement of its next phase in order to develop biomarker with Merck KgaA, along with Pfizer Inc., this collaboration will support the company in test discovery along with artificial intelligence and their applications to immunotherapy.
Impact of COVID-19 on the Global Diagnostic Biomarker Market
The global diagnostic biomarker market was positively affected by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had led to an increase in the demand for diagnostic biomarker in application across the globe with the demand for advanced and enhanced features. The hospitals also have a greater number of diagnostic procedures witnessed as many people admitted due to COVID-19 specially the old age group.
Segmental outlook
The market is segmented based on application, diagnostic technique and end-user. Based on application, the market is segmented oncology, cardiology, neurology, nephrology and other. By diagnostic technique, the market is segmented into Elisa, colorimetric assay, liquid chromatography-mass spectrometry, and particle-enhanced turbidimetric immunoassay and other. By end-user, market is segmented into hospitals & diagnostic labs and research centers.
Global Diagnostic Biomarker Market Share by Application 2020 (%)
Based on the application, oncology holds a significant market share. It is mostly used in the hospitals for providing proper effective diagnostic procedures to assist the patient. With the increasing pervasiveness of cancer across the globe the scope of oncology segment has also increased. According to American cancer society data across the globe an estimated 19.3 million new cancer cases occurred in 2020. A cancer biomarker supports in measuring the risk of developing cancer in a specific tissue for providing effective treatment to patients.
Regional Outlooks
The global diagnostic biomarker market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global diagnostic biomarker market. Some factors that are boosting the market growth in North America are growing cancer patients among population; leading manufactures and players present in the region. According to statistical data of 2020 provide by American Cancer Society in the US that highlighted around 1,806,590 new cancer cases. Additionally, well developed infrastructure of health that has led to rising healthcare R&D investments is other factors that are promoting the growth of the market.
Global Diagnostic Biomarker Market, by Region 2021-2027
Asia-Pacific will have Considerable Growth in the Global Diagnostic Biomarker Market
Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing pervasiveness of chronic diseases such as cancer cases in India, China and South Korea along with rising health care expenditure in emerging economies of the region is likely to drive the growth of the regional market. Further due to high government investments in R&D and rising adoption of personalized medicine especially in china are other prime factors that are driving the growth of the market in this region.
Market Player Outlook
Key players of the global diagnostic biomarker market are Abbott, F. Hoffmann-La Roche Ltd, Merck KgaA, SIGNOSIS INC., and QIAGEN among others. To survive in the market, these players adopt different marketing strategies such as product launches. For instance, in April 2021, F. Hoffmann-La Roche Ltd. had notified to introduce Elecsys Anti-p53 immunoassay. This will support in offering various type of diagnose related with cancers that includes oesophageal cancer and bowel cancer among others in patients along with different type of diagnostic tests. Additionally, the Elecsys Anti-p53 immunoassay will also support in monitoring the cancer cell remnants in the body of patients that is suffering from cancer.
In April 2021, F. Hoffmann-La Roche Ltd. had received the approval from U.S. Food and Drug Administration (FDA) in order to identify endometrial cancer among the patients through companion diagnostic. VENTANA MMR RxDx Panel was launch with the support and collaboration with GlaxoSmithKline (GSK) in order to provide help to patients suffering from endometrial cancer as they have limited options related to their treatment. Through this collaboration both the company have got into healthcare strategy in order to offer assistance through specific therapy.
In January 2021, Astellas Pharma Inc. had come up with the collaboration with regards to research with Actinium Pharmaceuticals, Inc., through this the company wants to develop theranostics to be the part of its business which is the combination of therapeutics along with diagnostics. With the support of this patients could get efficient and effective treatment with the proper guidance by healthcare professionals.
The Report Covers
• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global diagnostic biomarker market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Diagnostic Biomarker Industry
• Recovery Scenario of Global Diagnostic Biomarker Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Diagnostic Biomarker Market by Application
5.1.1. Oncology
5.1.2. Cardiology
5.1.3. Neurology
5.1.4. Nephrology
5.1.5. Other
5.2. Global Diagnostic Biomarker Market by Diagnostic Technique
5.2.1. Elisa
5.2.2. Colorimetric Assay
5.2.3. Liquid Chromatography-Mass Spectrometry
5.2.4. Particle-Enhanced Turbidimetric Immunoassay
5.2.5. Other
5.3. Global Diagnostic Biomarker Market by End-User
5.3.1. Hospitals & Diagnostic Labs
5.3.2. Research Centers
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Abbott
7.2. Astellas Pharma Inc.
7.3. Astute Medical, In
7.4. Agendia.
7.5. Avacta Life Sciences Ltd.
7.6. BANYAN BIOMARKERS
7.7. Bayer AG
7.8. Beckman Coulter, Inc
7.9. Biodesix
7.10. Biomarker Technologies, Inc.
7.11. bioMerieux SA
7.12. BioPorto A/S
7.13. Covance Inc
7.14. DIAGENIC ASA
7.15. Enzo Life Sciences, Inc.,
7.16. EUROIMMUN Medizinische Labordiagnostika AG
7.17. Exact Sciences Corp.
7.18. F. Hoffmann-La Roche Ltd
7.19. Illumina, Inc.
7.20. Inova Diagnostics
7.21. Life Diagnostics 20
7.22. Luminex Corp.
7.23. Merck KgaA
7.24. Myriad Genetics, Inc
7.25. NanoString
7.26. Novartis AG
7.27. Plato BioPharma
7.28. R&D Systems
7.29. RESPONSE BIOMEDICAL
7.30. Siemens Healthcare GmbH
7.31. SIGNOSIS INC.
7.32. StageZero Life Sciences, LLC
7.33. QIAGEN
1. GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
2. GLOBAL DIAGNOSTIC BIOMARKER MARKET BY APPLICATION, 2020-2027($ MILLION)
3. GLOBAL ONCOLOGY MARKET BY REGION, 2020-2027($ MILLION)
4. GLOBAL CARDIOLOGY MARKET BY REGION, 2020-2027($ MILLION)
5. GLOBAL NEUROLOGY MARKET BY REGION, 2020-2027($ MILLION)
6. GLOBAL NEPHROLOGY MARKET BY REGION, 2020-2027($ MILLION)
7. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
8. GLOBAL DIAGNOSTIC BIOMARKER MARKET BY DIAGNOSTIC TECHNIQUE, 2020-2027($ MILLION)
9. GLOBAL ELISA MARKET BY REGION, 2020-2027($ MILLION)
10. GLOBAL COLORIMETRIC ASSAY MARKET S BY REGION, 2020-2027($ MILLION)
11. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET BY REGION, 2020-2027($ MILLION)
12. GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY BY REGION, 2020-2027($ MILLION)
13. GLOBAL OTHER MARKET BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL DIAGNOSTIC BIOMARKER MARKET BY END USER, 2020-2027($ MILLION)
15. GLOBAL HOSPITALS&DIAGNOSTIC LABS MARKET BY REGION, 2020-2027($ MILLION)
16. GLOBAL RESEARCH CENTRES MARKET BY REGION, 2020-2027($ MILLION)
17. GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
18. NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
19. NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
20. NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2020-2027($ MILLION)
21. NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
22. EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
23. EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
24. EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2020-2027($ MILLION)
25. EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
26. ASIA-PACIFIC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
27. ASIA-PACIFIC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
28. ASIA-PACIFIC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2020-2027($ MILLION)
29. ASIA-PACIFIC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
30. REST OF WORLD DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
31. REST OF WORLD DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2020-2027($ MILLION)
32. REST OF WORLD DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL DIAGNOSTIC BIOMARKER MARKET, 2020-2027 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY SEGMENT, 2020-2027 ($ MILLION)
3. RECOVERY OF GLOBAL DIAGNOSTIC BIOMARKER MARKET, 2021-2027 (%)
4. GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
5. GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2020 VS 2027 (%)
6. GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY END-USER, 2020 VS 2027 (%)
7. GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL ONCOLOGY MARKET BY REGION, 2020 VS 2027 (%)
9. GLOBAL CARDIOLOGY MARKET BY REGION, 2020 VS 2027 (%)
10. GLOBAL NEUROLOGY MARKET BY REGION, 2020 VS 2027 (%)
11. GLOBAL NEPHROLOGY MARKET BY REGION, 2020 VS 2027 (%)
12. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
13. GLOBAL ELISA MARKET BY REGION, 2020 VS 2027 (%)
14. GLOBAL COLORIMETRIC ASSAY MARKET BY REGION, 2020 VS 2027 (%)
15. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET BY REGION, 2020 VS 2027 (%)
16. GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY MARKET BY REGION, 2020 VS 2027 (%)
17. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
18. GLOBAL HOSPITALS &DIAGNOSTIC LABS MARKET BY REGION, 2020 VS 2027 (%)
19. GLOBAL RESEARCH CENTRES MARKET BY REGION, 2020 VS 2027 (%)
20. US DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
21. CANADA DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
22. UK DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
23. FRANCE DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
24. GERMANY DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
25. ITALY DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
26. SPAIN DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
27. REST OF EUROPE DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
28. INDIA DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
29. CHINA DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
30. JAPAN DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
31. SOUTH KOREA DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
32. REST OF ASIA-PACIFIC DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
33. REST OF THE WORLD DIAGNOSTIC BIOMARKER MARKET SIZE, 2020-2027 ($ MILLION)
